2025-06-09-Jefferies-英思美公司（INSM）_6月TPIP肺动脉高压数据_我们认为获胜可能性很大_54页_2mb

报告摘要

Target: TPIP Inhaler for PAH: Treprostinil Palmitil Inhalation Powder (TPIP) is reformulated to improve tolerability, dosing convenience, and patient compliance compared to Tyvaso. Primary endpoint is a placebo-adjusted 20% reduction in pulmonary vascular resistance (PVR) in the Phase 2 PAH trial, expected topline in June 2025.
KOL Opinion: Favorable tolerability and a clear efficacy profile (20% PVR reduction) could serve as a winning case against Tyvaso, with the potential for 30% clinical adoption in PAH.
Market Opportunity: Analysts project $1.6B risk-adjusted peak sales for TPIP in PAH and PH-ILD by 2035.

1. TPIP Drug Profile

Mechanism: Prostacyclin analog with derisked mechanism due to approved prostacyclin therapies (e.g., Tyvaso).
Attributes: Longer half-life (one daily dose vs. four doses for Tyvaso), superior tolerability, and convenient dosing.
Unmet Needs: Addresses challenges in PAH treatment, including limited efficacy and high costs of existing therapies.

2. TPIP PAH Trial

Study Design: N=102, Phase 2 trial, primary endpoint: ≥20% PVR reduction.
Blinded Data Analysis:
- Favorable tolerability seen in 79% of patients.
- Regression and scenario analyses suggest high probability (>70%) of ≥20% PVR reduction.
- secondary endpoint: 15-20m directional improvement in 6MWD (not statistically powered).
Post-Hoc KOL Validation: Complementary to Tyvaso’s benchmark efficacy; 20% PVR + 20m 6MWD required for homerun results.
Analyst View: TPIP builds a winning case vs. Tyvaso due to favorable safety/safety superiority, dosing convenience (+ compliance), and lower acquisition costs.

3. Market Opportunity & Pricing

PAH/PH-ILD Market: ~350K PAH + 50K PH-ILD patients globally.
Revenue Projections: Consensus estimate: ~$1.6B peak sales by 2035 (40% PoS in PAH, 50% in PH-ILD).
DCF Model: Rating BUY, with a $105 PT (up 43% from current $73.62).

4. Valuation

WACC/DCF Sensitivity: 11% WACC used; worst-case scenarios include delayed data or minimal PVR/6MWD efficacy.
Other Catalysts: Brensocatib’s 2025 PA bronchiectasis approval, ARIKAYCE expansion in MAC lung disease.

TPIP has significant upside potential driven by the Phase 2 PAH topline in June 2025, bearing the risk profile typical for clinical-stage biotechs but supported by the maturity of the treprostinil mechanism across pulmonary diseases.

展开完整摘要